| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $33,144,763 | 4 | 100 |
Sells | $0 | 0 | 0 |
| CHILDS JOHN W | director | 1 | $25M | 0 | $0 | $25M |
| Coric Vlad | Chief Executive Officer | 1 | $5M | 0 | $0 | $5M |
| Bailey Gregory | director | 1 | $3M | 0 | $0 | $3M |
| Clark George C. | VP, Chief Accounting Officer | 1 | $144,770 | 0 | $0 | $144,770 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Over the last 12 months, insiders at Biohaven Ltd. have bought $33.14M and sold $0 worth of Biohaven Ltd. stock.
On average, over the past 5 years, insiders at Biohaven Ltd. have bought $28.89M and sold $8.84M worth of stock each year.
Highest buying activity among insiders over the last 12 months: CHILDS JOHN W (director) — $25M. Coric Vlad (Chief Executive Officer) — $5M. Bailey Gregory (director) — $3M.
The last purchase of 17,000 shares for transaction amount of $144,770 was made by Clark George C. (VP, Chief Accounting Officer) on 2025‑11‑17.
| 2025-11-17 | Clark George C. | VP, Chief Accounting Officer | 17,000 0.0165% | $8.52 | $144,770 | +36.09% | ||
| 2025-11-13 | CHILDS JOHN W | director | 3.33M 2.9193% | $7.50 | $25M | +38.49% | ||
| 2025-11-13 | Bailey Gregory | director | 400,000 0.3503% | $7.50 | $3M | +38.49% | ||
| 2025-11-13 | Coric Vlad | Chief Executive Officer | 666,666 0.5839% | $7.50 | $5M | +38.49% | ||
| 2025-03-04 | CHILDS JOHN W | director | 28,400 0.0273% | $30.43 | $864,115 | -53.11% | ||
| 2024-12-30 | CHILDS JOHN W | director | 29,000 0.0281% | $35.94 | $1.04M | -56.01% | ||
| 2024-10-02 | Coric Vlad | Chief Executive Officer | 21,052 0.0215% | $47.50 | $999,970 | -52.63% | ||
| 2024-10-02 | CHILDS JOHN W | director | 21,052 0.0215% | $47.50 | $999,970 | -52.63% | ||
| 2024-09-24 | Bailey Gregory | director | 5,000 0.0047% | $44.19 | $220,966 | -38.02% | ||
| 2024-07-18 | CHILDS JOHN W | director | 28,400 0.0218% | $35.67 | $1.01M | +6.44% | ||
| 2024-06-17 | Car Bruce | Chief Scientific Officer | 30,000 0.0217% | $33.58 | $1.01M | +13.11% | ||
| 2024-05-30 | CHILDS JOHN W | director | 28,000 0.0214% | $35.58 | $996,240 | +5.92% | ||
| 2024-05-13 | CHILDS JOHN W | director | 28,500 0.0215% | $35.17 | $1M | +11.81% | ||
| 2024-05-13 | Bailey Gregory | director | 15,000 0.011% | $34.19 | $512,877 | +11.81% | ||
| 2024-04-24 | Bailey Gregory | director | 25,503 0.0215% | $39.18 | $999,169 | -1.32% | ||
| 2024-04-22 | Coric Vlad | Chief Executive Officer | 121,951 0.1075% | $41.00 | $5M | -0.05% | ||
| 2024-04-22 | Bailey Gregory | director | 48,780 0.043% | $41.00 | $2M | -0.05% | ||
| 2024-04-22 | CHILDS JOHN W | director | 73,170 0.0645% | $41.00 | $3M | -0.05% | ||
| 2023-12-29 | Sale | Antonijevic Irina | director | 11,000 0.0099% | $41.79 | $459,663 | -0.12% | |
| 2023-10-05 | CHILDS JOHN W | director | 454,545 0.2149% | $22.00 | $10M | +61.12% |
| CHILDS JOHN W | director | 5653904 3.7552% | $88.71M | 22 | 2 | +13.66% |
| Bailey Gregory | director | 2020071 1.3417% | $31.69M | 10 | 22 | +9.89% |
| Coric Vlad | Chief Executive Officer | 1195275 0.7939% | $18.75M | 9 | 8 | +10.59% |
| Clark George C. | VP, Chief Accounting Officer | 20000 0.0133% | $313,800.00 | 1 | 3 | |
| Cha Albert | director | 1976818 1.313% | $31.02M | 1 | 0 | |
| Doogan Declan | director | 870648 0.5783% | $13.66M | 0 | 31 | |
| Buten Matthew | Chief Financial Officer | 189380 0.1258% | $2.97M | 2 | 0 | +39.3% |
| PORTAGE BIOTECH INC. | 54494 0.0362% | $855,010.86 | 0 | 7 | ||
| Car Bruce | Chief Scientific Officer | 30000 0.0199% | $470,700.00 | 1 | 0 | +13.11% |
| GREGORY JULIA P | director | 25665 0.017% | $402,683.85 | 1 | 3 | +17.49% |
| Engelhart James | Chief Financial Officer | 11196 0.0074% | $175,665.24 | 2 | 9 | |
| Stock Elyse | Chief Medical Officer | 7467 0.005% | $117,157.23 | 0 | 5 | |
| Conway Charles | Chief Scientific Officer | 4000 0.0027% | $62,760.00 | 1 | 0 | |
| Gentile Kimberly | SVP, Clinical Operations | 3639 0.0024% | $57,095.91 | 0 | 11 | |
| Antonijevic Irina | director | 2535 0.0017% | $39,774.15 | 0 | 1 | |
| JONES WILLIAM A JR | CCO-Migraine & Common Disease | 1755 0.0012% | $27,535.95 | 0 | 1 | |
| AGUIAR ERIC | director | 1250 0.0008% | $19,612.50 | 0 | 7 | |
| Tilton John | Chief Commercial Officer | 770 0.0005% | $12,081.30 | 0 | 4 | |
| Berman Robert | Special Projects & Med Ovrsght | 341 0.0002% | $5,350.29 | 2 | 22 |
$607,257,766 | 94 | 3.69% | $2.53B | |
$21,345,882 | 83 | 94.45% | $2.53B | |
$52,263,649 | 70 | 1.18% | $2.23B | |
$54,660,406 | 66 | 22.24% | $2.33B | |
$47,419,530 | 58 | 17.20% | $2.38B | |
$108,353,116 | 49 | 15.41% | $2.15B | |
$613,304,943 | 46 | 11.85% | $2.21B | |
$678,065,999 | 37 | -13.32% | $2.45B | |
$154,047,855 | 36 | 79.21% | $2.58B | |
$27,136,525 | 32 | 36.73% | $2.36B | |
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) | $105,063,207 | 29 | 14.02% | $2.36B |
$9,463,680 | 28 | 0.72% | $2.56B | |
$2,788,839 | 12 | 6.73% | $2.13B | |
$69,805,526 | 11 | 41.69% | $2.49B | |
$1,580,951 | 9 | -14.18% | $2.15B | |
$2,111,366 | 7 | 21.26% | $2.08B | |
$25,073,947 | 7 | -5.99% | $2.45B | |
$162,238 | 3 | 144.37% | $2.19B | |
$152,517 | 2 | 177.13% | $2.26B |
| Increased Positions | 193 | +72.01% | 55M | +64.44% |
| Decreased Positions | 120 | -44.78% | 20M | -23.1% |
| New Positions | 75 | New | 15M | New |
| Sold Out Positions | 61 | Sold Out | 10M | Sold Out |
| Total Postitions | 341 | +27.24% | 120M | +41.34% |
| Blackrock, Inc. | $85,364.00 | 5.92% | 7.87M | +339,618 | +4.51% | 2025-09-30 |
| Janus Henderson Group Plc | $73,410.00 | 5.09% | 6.77M | +2M | +34.01% | 2025-09-30 |
| Stifel Financial Corp | $71,667.00 | 4.97% | 6.61M | +3,839 | +0.06% | 2025-09-30 |
| Suvretta Capital Management, Llc | $60,924.00 | 4.23% | 5.62M | 0 | 0% | 2025-09-30 |
| State Street Corp | $46,160.00 | 3.2% | 4.26M | +720,120 | +20.35% | 2025-09-30 |
| Vanguard Group Inc | $31,167.00 | 2.16% | 2.88M | -6M | -68.92% | 2025-09-30 |
| Bellevue Group Ag | $30,383.00 | 2.11% | 2.8M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $26,308.00 | 1.83% | 2.43M | +761,991 | +45.77% | 2025-09-30 |
| Geode Capital Management, Llc | $22,333.00 | 1.55% | 2.06M | +29,289 | +1.44% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $21,784.00 | 1.51% | 2.01M | -1M | -36.63% | 2025-09-30 |